Innovative State and Local Public Health Strategies to prevent and Manage Diabetes and Heart Disease and Stroke-

 

The purpose of this program is to design, test, and evaluate novel approaches to addressing a set of evidence based strategies aimed at reducing risks, complications, and/or barriers to prevention and control of diabetes and cardiovascular disease among high-burden populations. The Selection of high burden populations will be based on a robust analysis of diabetes and cardiovascular health burden across geographic areas and population subgroups. Population subgroups may be defined by factors such as race or ethnicity, gender, age [e.g. youth and older adults], education, income, disability, or sexual orientation, among others.

Active 93.435 Centers For Disease Control and Prevention, Department of Health and Human Services B - Project Grants Not applicable. Section 301(a) of the Public Health Service Act [42] U.S.C. Section 241(a) Title IV Section 4002 of the Affordable Care Action, Prevention and Public Health Fund
n/a State or local health departments or their Bona Fide Agents (includes the District of Columbia) Eligibility will be limited to state and local/city/county governments with a population of 900,000 or more with the greatest potential to reach and impact large numbers of high risk/high burden populations, or their bona fide agents. Consortia of smaller local/city/county health departments may collaborate to submit one application that, collectively, represents a population of 900,000 or more. Beneficiaries of this program include: State, Local, Individual/Family, Minority Group, Anyone/General Public, Black American, American Indian, Spanish Origin, Oriental, Other Nonwhite, Women, Handicapped, Physically Afflicted, Senior Citizen, Rural Not applicable. Preapplication coordination is required. This program is eligible for coverage under E.O. 12372, "Intergovernmental Review of Federal Programs." An applicant should consult the office or official designated as the single point of contact in his or her State for more information on the process the State requires to be followed in applying for assistance, if the State has selected the program for review. n/a 2 CFR 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards applies to this program. n/a Review and Selection Process: Applications will be reviewed in three phases. Phase I Review: All applications will be reviewed initially for completeness by CDC OGS staff and will be reviewed jointly for eligibility by the CDC National Center for Chronic Disease Prevention and Health Promotion and CDC OGS. Incomplete applications that do not meet the eligibility criteria will not advance to Phase II review. Phase II Review: This NOFO includes strategies in two categories, Category A (diabetes management and type 2 diabetes prevention strategies) and Category B (cardiovascular disease prevention and management strategies). In both categories, applicants will select from a menu of strategies. Applications will be competitive and will support the implementation and evaluation of work on a small set of innovative strategies designed to reduce risks, complications, and/or barriers to prevent and control diabetes and prevention of heart disease and stroke. Applications will undergo an objective review panel process to evaluate complete and responsiveness according to the criteria section of the funding opportunity. Phase III Review: Applications will be funded in order by score and rank determined by the objective review panel. The Selecting official shall rely on the rank order established by the objective review panel as the primary factor in making awards Contact the headquarters or regional location, as appropriate for application deadlines From 120 to 180 days. n/a Not applicable. From 120 to 180 days. n/a Review and Selection Process: Applications will be reviewed in three phases. Phase I Review: All applications will be reviewed initially for completeness by CDC OGS staff and will be reviewed jointly for eligibility by the CDC National Center for Chronic Disease Prevention and Health Promotion and CDC OGS. Incomplete applications that do not meet the eligibility criteria will not advance to Phase II review. Phase II Review: This NOFO includes strategies in two categories, Category A (diabetes management and type 2 diabetes prevention strategies) and Category B (cardiovascular disease prevention and management strategies). In both categories, applicants will select from a menu of strategies. Applications will be competitive and will support the implementation and evaluation of work on a small set of innovative strategies designed to reduce risks, complications, and/or barriers to prevent and control diabetes and prevention of heart disease and stroke. Applications will undergo an objective review panel process to evaluate complete and responsiveness according to the criteria section of the funding opportunity. Phase III Review: Applications will be funded in order by score and rank determined by the objective review panel. The Selecting official shall rely on the rank order established by the objective review panel as the primary factor in making awards. Funds for this program are to be used to design, test, and evaluate novel approaches to addressing a set of evidence based strategies aimed at reducing risks, complications, and/or barriers to prevention and control of diabetes and cardiovascular disease among high-burden populations. Performance Reports: Annual performance progress and monitoring reports will be expected from all awardees no later than 120 days prior to the end of each budget period. This report will serve as the continuation application for the follow-on budget period. The contents of the report should include the information specified in the solicitation from the CDC Grants Management Officer. CDC requires awardees to meet all record retention requirements defined in the notice of award, the funding opportunity, the HHS grants policy statement, and 45 CFR Part 75. CDC requires awardees to meet all record retention requirements defined in the notice of award, the funding opportunity, the HHS grants policy statement, and 45 CFR Part 75. Statutory formula is not applicable to this assistance listing.

Matching requirements are not applicable to this assistance listing.

MOE requirements are not applicable to this assistance listing. Funding for this program will be awarded on annual basis and the funding will be available for obligation by recipients for a period of 12-months. Recipients will receive an electronic copy of the notice of award from CDC OGS. The notice of award shall be the only binding, authorizing document between the awardee and CDC. The notice of award will be signed by an authorized grants management officer and e-mailed to the awardee Principal Investigator and business official. The notice of award is expected to be complete 30-days in advance of the project period start date of September 30, 2018. Method of awarding/releasing assistance: Lump. n/a Robert Hancock
4770 Buford Highway, MS F75
Atlanta, GA 30341 US
rnh2@cdc.gov
Phone: 7704887431 http://www.cdc.gov 75-0943-0-1-550 (Cooperative Agreements) FY 18$39,928,477.00; FY 19 est $41,528,477.00; FY 20 est $41,528,477.00; FY 17$0.00; - This new program is being funded by two divisions DDT and DHDSP. (DP18-1817) Awards for this new program are expected to range from $1,000,000 to $3,500,000. Awards will be based on activities proposed by the applicant, the burden of disease of diabetes and heart disease and stroke, and the recipient's potential reach and effect outcomes for large numbers of adults. Not applicable. Not applicable.